Genprex, Inc. (NASDAQ: GNPX), an Austin, Texas-based developer of immunogene therapy for non-small cell lung cancer, raised $10m in a private placement.
Undisclosed institutional investors participated in the private placement of shares of its common stock and warrants.
Maxim Group LLC is acting as the exclusive placement agent for the transaction.
Genprex is a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, including the initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC).
Its platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.